Latest news and press releases about Acrivon Therapeutics, Inc. Common Stock (ACRV): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool.
Price
| Price | $1.70 |
| Market Cap | $73M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.81 |
| EV / EBITDA | -0.66 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -70.14% |
| Return on Invested Capital | -88.28% |
| Return on Assets | -74.91% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATYR · BMEA · CBUS · IMUX · PMVP · RLMD · RPTX
Explore sector: Healthcare · Biotechnology
More sections of ACRV: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks